Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
about
t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemiaBurkitt lymphoma in adolescents and young adults: management challenges.Primary burkitt lymphoma of the chest wall.Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic LeukemiaRituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.Novel therapies for relapsed acute lymphoblastic leukemia.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialBurkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993T cell acute lymphoblastic leukaemia presenting with sudden onset right oculomotor nerve palsy with normal neuroradiography and cerebrospinal fluid studiesA retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center.High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies.Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.Lymphoma of the urinary bladder.Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Emerging therapy for the treatment of acute lymphoblastic leukemia.Molecular profiling of aggressive lymphomasThe role of hematopoietic SCT in adult Burkitt lymphoma.Burkitt's lymphoma of the ovary: case report and review of the literature.Clinical management of HIV-associated hematologic malignancies.Methotrexate Elimination When Coadministered With Levetiracetam.Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffusePrimary ovarian Burkitt's lymphoma: a rare oncological problem in gynaecology: a review of literature.Clinical aspects and therapy of sporadic burkitt lymphomaBurkitt's lymphoma: single-centre experience with modified BFM protocol.Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation.Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy.Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
P2860
Q21245731-FAF2321D-EB60-40BA-ABCA-207F0F487242Q30238965-D363DF45-F0D2-4841-9A96-0499927EEFAEQ30425404-9A0D21D7-863C-45C8-AC7B-1DD411082128Q30540646-9C1CC009-84FF-4953-B419-19F3322051C1Q33341768-7EF9130E-6CA7-43A6-872D-4580F20051BCQ33583302-9E7F8236-663E-4682-AECD-EE0CAA52A56BQ33736847-F0700F01-F8E3-4C3A-ACE8-6FFCC1B95CCDQ33806007-B5C1BA9A-95D1-456B-9C6C-CCC1D685E57DQ33828585-1722F307-6638-493E-AADD-4F37C63D5194Q34018599-A2855DE8-3982-439F-B0D6-7B219136E37CQ34522797-5DE51485-951E-4C33-930C-12DC2E2F7685Q34526281-FDCF8FAC-CD5E-42D6-98BF-A2298F609288Q34619129-3BB10C89-F0BA-42A8-B665-8CDCCD30E7F9Q34737471-641967D5-67D0-4A7D-815E-B6586199A00AQ35384536-C137E9AC-7D1C-4C74-8FA8-E1658B3F8071Q35429833-569F2632-DC37-4A60-8BCF-91C6CFCCF906Q35606384-F7A30F71-B20A-4360-881F-F27215242A46Q35836856-D1639853-654F-4053-B03E-E077E0A92CFFQ35848955-676602FA-6DB0-47F6-BE21-C494DBAF02BFQ35863508-628135BF-FCD7-4899-9285-D931ADE81667Q35931539-D432754E-265F-4B32-B2C1-C5C6F80C2852Q37273182-6A3367E0-ACDA-4538-96A7-CED332E5F754Q37404397-0F6DE72A-AEE5-47BE-840B-1469CA883230Q37476684-F76D5C83-93B9-4473-A8DF-72DD16C2F459Q37551555-E8D4B71A-EAAC-4B90-99E7-E3709B4BF524Q37572226-928E34A9-03CA-456A-86F1-96CE2DD20B68Q37613872-AE9E3ECB-92A8-41C5-AA81-A7791079F63AQ37670194-1B95893D-6375-444D-BF2F-54376D86B65EQ37970680-8963B118-B566-46CF-B814-740CF1541369Q38031733-6E84E53D-5A0E-4689-856F-359C4CD50CA4Q38069037-C2301E63-FC3F-4B1C-90BC-10EEBAD8A918Q38664912-173ED28A-F423-4878-B927-3F33F9C942ADQ38924367-C66ECD7F-506E-45E4-8815-331FAABE7315Q39452113-7EC2C9FD-2952-4A2A-8959-BC356B56DA9FQ40096953-7E66A8F0-BD3A-4453-ADDF-6E65BCA1E5E8Q42588955-40C09A28-05BB-48F1-AD0D-F644D1380595Q43977187-D314BDA4-360D-4E11-AEB2-CC1DF10EA145Q44086103-D4383A9B-A85A-4352-BC69-D83CF4C2A2E6Q44923993-1E056EE8-62BD-4CDC-9EFA-0FC937389B01Q46412975-711C40B7-FCFC-4A85-8325-0D81B5229D39
P2860
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@ast
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@en
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@nl
type
label
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@ast
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@en
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@nl
prefLabel
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@ast
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@en
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@nl
P2093
P1476
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
@en
P2093
D A Thomas
F B Hagemeister
F F Cabanillas
H Kantarjian
M J Keating
P304
P356
10.1200/JCO.1999.17.8.2461
P407
P577
1999-08-01T00:00:00Z